NEW YORK (GenomeWeb) – Trovagene announced after the close of the market on Wednesday a 14 percent year-over-year drop in fourth quarter revenues. The firm also announced a restructuring program to expand into precision cancer drug development.

The liquid biopsy molecular diagnostics developer said its revenues were $68,000 for the three  months ended Dec. 31, 2016, compared to $79,000 in Q4 2015, and significantly short of the analysts' average estimate of $180,000.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.